報價延遲最少15分鐘:2026/04/21 21:41 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
20.68 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-7.13/1.95
|
|
企業價值
3.28B
|
| 資產負債 |
|
每股賬面淨值
10.86
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
2.20B
|
|
每股收益
10.52
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases. |
